In patients with platinum-sensitive BRCA-mutated relapsed ovarian cancer, olaparib maintenance therapy significantly increased median overall survival compared with placebo, according to results of the final analysis of the phase 3 SOLO2/ENGOT Ov-21 trial to be presented this coming weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.The trial enrolled 295 patients with BRCA-mutated relapsed ovarian cancer who were previously treated with at least two line...

Olaparib (Lynparza®, AstraZeneca Pharmaceuticals, LP), in combination with bevacizumab (Avastsin®, Genentech), is now FDA approved as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had a complete or partial response to first-line platinum-based chemotherapy. Patients must also have cancer that is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or ...

The FDA has now expanded the approval of niraparib (Zejula®, GlaxoSmithKline) to include maintenance therapy for adults with metastatic epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. This frontline maintenance approval adds to previous approvals for third-line or later maintenance therapy in these cancers regardless of HRD...

​In recent years, a number of lawsuits have highlighted concerns regarding a possible link between ovarian cancer risk and the use of talc-containing cosmetic powders in the genital area. However, a large pooled analysis now published in JAMA reports no statistically significant association between genital powder use and ovarian cancer.The potential connection between genital powder use and ovarian cancer risk was first investigated because of the relationship between talcum powder and asbestos,...

A phase 3 trial reports that olaparib as maintenance therapy in combination with bevacizumab increases progression-free survival (PFS) in patients with newly diagnosed, advanced high-grade ovarian cancer both with and without BRCA mutations.While previous studies have found that maintenance olaparib is associated with improved outcomes in patients with ovarian cancer with BRCA mutations, its efficacy in patients without BRCA mutations had not been confirmed. In the phase 3 PAOLA-1 trial, a team ...